Related to FDA Significantly Restricts Access to GSK’s Antidiabetic Avandia

• EC Clears HGS and GSK’s Systemic Lupus Erythematosus Antibody Therapy Benlysta
  
• FDA Issues Transcept a Second CRL for Sleep-Aid Drug Intermezzo
  
• FDA Approves AstraZeneca’s Antiplatelet Drug
  
• EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk
  
• FDA Clears Self-Injectable Formulation of BMS’ Rheumatoid Arthritis Drug
  
• Genentech Takes Another Shot at Convincing FDA to Maintain Avastin’s Metastatic Breast Cancer Approval
  
• FDA Issues Adventrx with Complete Response Letter for NSCLC Drug Candidate
  
• FDA Approves Gilead’s Single-Tablet Triple HIV Therapy Complera
  
• FDA Okays Gilead’s San Dimas, CA, Site for Continued Operation
  
• FDA Green-Lights Roche’s Melanoma Drug and Companion Diagnostic
  
• FDA Details Strategy for Overhauling Regulatory Science Used in Review Process
  
• Seattle Genetics’ Antibody-Drug Conjugate Receives FDA Okay to Treat Lymphomas
  
• FDA Sanctions Abbott's Genetic FISH Panel for Leukemia Prognosis
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe
  
• FDA Issues Novartis with CRL Requesting Additional Safety Data on Gouty Arthritis Drug
  
• NuPathe Shares Plunge After Launch of Migraine Patch Delayed
  
• FDA Gives Amgen’s Prolia the Go-Ahead in Two Cancer Therapy-Induced Bone Loss Indications
  
• FDA Details “Reasonable and Feasible” Trial Design for Orexigen’s Obesity Drug Contrave
  
• FDA Clears Alexion’s Soliris for All Patients with Atypical Hemolytic Uremic Syndrome
  
• FDA Clears Lilly’s Cialis for Treating Symptoms of BPH in Men with or without Erectile Dysfunction